# AMERICAN BATTERY TECHNOLOGY Co: financial statements, quarterly

ABAT · Nasdaq · CIK 1576873 · [Materials](/sectors/materials.md) · fiscal year ends Jun 30

Pages: [Overview](/companies/abat.md) · [Financials](/companies/abat/financials.md) · [Filings](/companies/abat/filings.md) · [Insiders](/companies/abat/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/abat/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | [0.2](/filings/0001493152-25-021111.md) | [0.3](/filings/0001493152-26-005349.md) | [1.0](/filings/0001493152-26-022149.md) | [2.8 d](/filings/0001493152-26-042497.md) | [0.9](/filings/0001493152-25-021111.md) | [4.8](/filings/0001493152-26-005349.md) | [7.8](/filings/0001493152-26-022149.md) | [8.2 d](/filings/0001493152-26-042497.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | [2.5](/filings/0001493152-25-021111.md) | [3.3](/filings/0001493152-26-005349.md) | [3.7](/filings/0001493152-26-022149.md) | [5.3 d](/filings/0001493152-26-042497.md) | [4.5](/filings/0001493152-25-021111.md) | [6.4](/filings/0001493152-26-005349.md) | [7.1](/filings/0001493152-26-022149.md) | [6.9 d](/filings/0001493152-26-042497.md) |
| Gross profit | $m | not reported | not reported | not reported | not reported | [(2.3)](/filings/0001493152-25-021111.md) | [(3.0)](/filings/0001493152-26-005349.md) | [(2.7)](/filings/0001493152-26-022149.md) | [(2.6) d](/filings/0001493152-26-042497.md) | [(3.5)](/filings/0001493152-25-021111.md) | [(1.6)](/filings/0001493152-26-005349.md) | [0.7](/filings/0001493152-26-022149.md) | [1.3 d](/filings/0001493152-26-042497.md) |
| Research and development | $m | [3.6](/filings/0001493152-24-046030.md) | [3.6](/filings/0001493152-25-006918.md) | [4.0](/filings/0001641172-25-011038.md) | [3.2 d](/filings/0001493152-25-014092.md) | [2.0](/filings/0001493152-25-021111.md) | [2.9](/filings/0001493152-26-005349.md) | [3.3](/filings/0001493152-26-022149.md) | [0.3 d](/filings/0001493152-26-042497.md) | [2.7](/filings/0001493152-25-021111.md) | [3.8](/filings/0001493152-26-005349.md) | [4.6](/filings/0001493152-26-022149.md) | [6.7 d](/filings/0001493152-26-042497.md) |
| Operating income | $m | [(8.0)](/filings/0001493152-24-046030.md) | [(8.8)](/filings/0001493152-25-006918.md) | [(8.6)](/filings/0001641172-25-011038.md) | [(22.3) d](/filings/0001493152-25-014092.md) | [(9.8)](/filings/0001493152-25-021111.md) | [(13.8)](/filings/0001493152-26-005349.md) | [(10.6)](/filings/0001493152-26-022149.md) | [(7.8) d](/filings/0001493152-26-042497.md) | [(10.1)](/filings/0001493152-25-021111.md) | [(9.9)](/filings/0001493152-26-005349.md) | [(34.4)](/filings/0001493152-26-022149.md) | [(20.3) d](/filings/0001493152-26-042497.md) |
| Interest expense | $m | [0.1](/filings/0001493152-24-046030.md) | [0.0](/filings/0001493152-24-006774.md) | [0.0](/filings/0001493152-24-020044.md) | [(0.1) d](/filings/0001493152-25-014092.md) | [0.0](/filings/0001493152-25-021111.md) | [(0.0)](/filings/0001493152-26-005349.md) | [0.0](/filings/0001493152-26-022149.md) | [(0.0) d](/filings/0001493152-26-042497.md) | [0.0](/filings/0001493152-25-021111.md) | [(0.3)](/filings/0001493152-26-005349.md) | [(0.3)](/filings/0001493152-26-022149.md) | [0.6 d](/filings/0001493152-26-042497.md) |
| Net income | $m | [(8.9)](/filings/0001641172-25-011038.md) | [(10.2)](/filings/0001641172-25-011038.md) | [(10.0)](/filings/0001641172-25-011038.md) | [(23.4) d](/filings/0001493152-25-014092.md) | [(11.7)](/filings/0001493152-26-022149.md) | [(13.4)](/filings/0001493152-26-022149.md) | [(11.5)](/filings/0001493152-26-022149.md) | [(10.2) d](/filings/0001493152-26-042497.md) | [(10.3)](/filings/0001493152-26-022149.md) | [(9.3)](/filings/0001493152-26-022149.md) | [(33.8)](/filings/0001493152-26-022149.md) | [(20.0) d](/filings/0001493152-26-042497.md) |
| Diluted EPS | $ per share | [(0.19)](/filings/0001493152-24-046030.md) | [(0.21)](/filings/0001493152-25-006918.md) | [(0.19)](/filings/0001641172-25-011038.md) | not reported | [(0.17)](/filings/0001493152-25-021111.md) | [(0.18)](/filings/0001493152-26-005349.md) | [(0.14)](/filings/0001493152-26-022149.md) | not reported | [(0.09)](/filings/0001493152-25-021111.md) | [(0.07)](/filings/0001493152-26-005349.md) | [(0.26)](/filings/0001493152-26-022149.md) | not reported |
| Basic EPS | $ per share | [(0.19)](/filings/0001493152-24-046030.md) | [(0.21)](/filings/0001493152-25-006918.md) | [(0.19)](/filings/0001641172-25-011038.md) | not reported | [(0.17)](/filings/0001493152-25-021111.md) | [(0.18)](/filings/0001493152-26-005349.md) | [(0.14)](/filings/0001493152-26-022149.md) | not reported | [(0.09)](/filings/0001493152-25-021111.md) | [(0.07)](/filings/0001493152-26-005349.md) | [(0.26)](/filings/0001493152-26-022149.md) | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating, us-gaap:InterestExpense
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | period not labelled (2024-11-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [7.6](/filings/0001493152-24-006774.md) | [6.0](/filings/0001493152-24-020044.md) | [7.0](/filings/0001493152-25-014092.md) | [5.8](/filings/0001493152-24-046030.md) | not reported | [20.6](/filings/0001493152-25-006918.md) | [7.8](/filings/0001641172-25-011038.md) | [7.5](/filings/0001493152-26-042497.md) | [30.9](/filings/0001493152-25-021111.md) | [47.9](/filings/0001493152-26-005349.md) | [37.7](/filings/0001493152-26-022149.md) | [49.5](/filings/0001493152-26-042497.md) |
| Current assets | $m | [11.6](/filings/0001493152-24-006774.md) | [10.3](/filings/0001493152-24-020044.md) | [18.4](/filings/0001493152-25-014092.md) | [15.5](/filings/0001493152-24-046030.md) | not reported | [30.5](/filings/0001493152-25-006918.md) | [23.3](/filings/0001641172-25-011038.md) | [29.5](/filings/0001493152-26-042497.md) | [41.5](/filings/0001493152-25-021111.md) | [63.1](/filings/0001493152-26-005349.md) | [53.4](/filings/0001493152-26-022149.md) | [60.9](/filings/0001493152-26-042497.md) |
| Total assets | $m | [88.9](/filings/0001493152-24-006774.md) | [89.3](/filings/0001493152-24-020044.md) | [77.7](/filings/0001493152-25-014092.md) | [73.8](/filings/0001493152-24-046030.md) | not reported | [88.3](/filings/0001493152-25-006918.md) | [76.5](/filings/0001641172-25-011038.md) | [84.5](/filings/0001493152-26-042497.md) | [101](/filings/0001493152-25-021111.md) | [123](/filings/0001493152-26-005349.md) | [119](/filings/0001493152-26-022149.md) | [133](/filings/0001493152-26-042497.md) |
| Current liabilities | $m | [22.3](/filings/0001493152-24-006774.md) | [17.0](/filings/0001493152-24-020044.md) | [15.8](/filings/0001493152-25-014092.md) | [10.0](/filings/0001493152-24-046030.md) | not reported | [17.4](/filings/0001493152-25-006918.md) | [10.6](/filings/0001641172-25-011038.md) | [13.7](/filings/0001493152-26-042497.md) | [5.3](/filings/0001493152-25-021111.md) | [4.2](/filings/0001493152-26-005349.md) | [6.6](/filings/0001493152-26-022149.md) | [6.4](/filings/0001493152-26-042497.md) |
| Total liabilities | $m | [22.3](/filings/0001493152-24-006774.md) | [19.2](/filings/0001493152-24-020044.md) | [16.2](/filings/0001493152-25-014092.md) | [14.5](/filings/0001493152-24-046030.md) | not reported | [17.7](/filings/0001493152-25-006918.md) | [10.9](/filings/0001641172-25-011038.md) | [13.9](/filings/0001493152-26-042497.md) | [5.5](/filings/0001493152-25-021111.md) | [4.4](/filings/0001493152-26-005349.md) | [6.7](/filings/0001493152-26-022149.md) | [6.5](/filings/0001493152-26-042497.md) |
| Long-term debt | $m | [19.7](/filings/0001493152-24-006774.md) | [12.5](/filings/0001493152-24-020044.md) | [7.1](/filings/0001493152-24-037818.md) | not reported | [2.1](/filings/0001493152-26-042497.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | [19.7](/filings/0001493152-24-006774.md) | [10.7](/filings/0001493152-24-020044.md) | [6.4](/filings/0001493152-24-037818.md) | [2.6](/filings/0001493152-24-046030.md) | not reported | [10.2](/filings/0001493152-25-006918.md) | [6.7](/filings/0001641172-25-011038.md) | [7.7](/filings/0001493152-25-014092.md) | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [65.6](/filings/0001641172-25-011038.md) | [71.6](/filings/0001641172-25-011038.md) | [61.5](/filings/0001493152-26-042497.md) | [59.3](/filings/0001493152-26-022149.md) | not reported | [70.6](/filings/0001493152-26-022149.md) | [65.6](/filings/0001493152-26-022149.md) | [70.6](/filings/0001493152-26-042497.md) | [96.0](/filings/0001493152-26-022149.md) | [119](/filings/0001493152-26-022149.md) | [113](/filings/0001493152-26-022149.md) | [126](/filings/0001493152-26-042497.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(4.8)](/filings/0001493152-24-046030.md) | [(2.7) d](/filings/0001493152-25-006918.md) | [(5.0) d](/filings/0001641172-25-011038.md) | [(4.3) d](/filings/0001493152-25-014092.md) | [(5.6)](/filings/0001493152-25-021111.md) | [(7.3) d](/filings/0001493152-26-005349.md) | [(10.3) d](/filings/0001493152-26-022149.md) | [(5.8) d](/filings/0001493152-26-042497.md) | [(7.1)](/filings/0001493152-25-021111.md) | [(9.8) d](/filings/0001493152-26-005349.md) | [(2.7)](/filings/0001493152-26-022149.md) | [(4.6) d](/filings/0001493152-26-042497.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported
- Dividends paid: not reported

## Shares

| Line item | Unit | Q1 FY2023 (2022-09-30) | Q2 FY2023 (2022-12-31) | Q3 FY2023 (2023-03-31) | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [42.9](/filings/0001493152-23-041335.md) | [43.2](/filings/0001493152-24-006774.md) | [43.5](/filings/0001493152-24-020044.md) | [46.1](/filings/0001493152-24-046030.md) | [47.8](/filings/0001493152-25-006918.md) | [52.0](/filings/0001641172-25-011038.md) | [69.5](/filings/0001493152-25-021111.md) | [75.3](/filings/0001493152-26-005349.md) | [85.1](/filings/0001493152-26-022149.md) | [112](/filings/0001493152-25-021111.md) | [129](/filings/0001493152-26-005349.md) | [132](/filings/0001493152-26-022149.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 142,577,758 at 2026-09-08, from the cover of the [10-K filed 2026-09-14](/filings/0001493152-26-042497.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.